msx-122
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00591682)
Timeline
Indications
Mechanism of action
- C-X-C chemokine receptor type 4ANTAGONIST
CXCR4 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
c1cnc(NCc2ccc(CNc3ncccn3)cc2)nc1- Mol. weight
- 292.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545330 ↗
Also known as
- msx-122
- msx-122
- msx-122
- msx-122
- msx-122
- n,n'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03518138 | Phase 2 | Aug 31, 2018 | Que Oncology, Syneos Health |
| NCT04080297 | Phase 1 | Jan 10, 2014 | Que Oncology |
| NCT00591682 | Phase 1 | Nov 1, 2007 | Altiris, University of Texas at Houston |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Que Oncology | For profit | 2 | 2 | 2 | 2014 |
| Altiris | For profit | 1 | 1 | 1 | 2007 |
| Syneos Health | For profit | 1 | 0 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2007 |
4 organizations
Page 1 / 1